Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D2 and 5-HT2A Receptor Occupancy in Schizophrenic Patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Meltzer HY, Matsubara S, Lee J-C: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390–392
Casey DE: Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 1989; 25:457–459
Gerlach J: New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17:289–309
Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF: Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244:685–693
Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661–670
Schotte A, Janssen PMF, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs—in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57–73
Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712–726
Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835
Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine—relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538–544
Nordström A-L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G: D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444–1449
Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B:5-HT2 and D2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology (Berl) 1993; 110:265–272
Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57:103–107
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Kerwin RW: Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride—an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1995; 117:55–61
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276
von Knorring L, Lindström E: The Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. Acta Psychiatr Scand 1992; 86:463–468
Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7:233
Huang M-L, Van Peer A, Woestenborghs RJ, De Coster R, Heykants JJ, Janssen AAI, Zylicz Z, Visscher HW, Jonkman JHG: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257–268
Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O: A comparative PET study of five carbon-11 or fluorine-18 labeled salicylamides: preparation and in vitro dopamine D-2 binding. Int J Rad Appl Instrum B 1991; 18:871–881
Nyberg S, Farde L, Halldin C: A PET study of 5HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1–7
Litton JE, Holte S, Eriksson L: Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B. IEEE Trans Nucl Sci 1990; 37:743–748
Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss W: The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18:110–118
Farde L, Eriksson L, Blomquist G, Halldin C: Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET—a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9:696–708
Andrée B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L: Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Pharmacol 1998; 18:317–323
Karlsson P, Farde L, Christer H, Sedvall G, Ynddal L, Sloth-Nielsen M: Oral administration of NNC 756—a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology (Berl) 1995; 119:1–8
Nordström A-L, Farde L, Pauli S, Litton J-E, Halldin C: PET analysis of central [11C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects. Hum Psychopharmacol 1992; 7:157–165
Nyberg S, Farde L, Halldin C: Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy: a PET study in haloperidol-treated patients. Psychiatry Res 1996; 67:163–171
Aravagiri M, Marder SR, Wirshing D, Wirshing WC: Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998; 31:102–109
Nyberg S, Farde L: The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed: commentary on “Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.” J Psychopharmacol 1997; 11:15–16